LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies aimed at improving vision for patients in the United States. The company's primary focus is on addressing unmet needs in ophthalmology, with a particular emphasis on age-related vision conditions. Its lead product candidates, LNZ100 and LNZ101, are currently undergoing Phase III clinical trials for the treatment of presbyopia, a common condition characterized by the gradual loss of the ability to focus on nearby objects. This represents a significant market opportunity given the aging global population. LENZ Therapeutics employs a development-stage business model, investing heavily in research and clinical trials to advance its pipeline. The company's strategic focus is on successfully completing these trials, securing regulatory approval, and ultimately bringing its innovative treatments to market. By targeting presbyopia, LENZ aims to establish a strong foothold in the ophthalmic therapeutics sector, potentially offering a non-surgical solution to a widespread visual impairment. The company was founded in 2013 and is headquartered in Solana Beach, California.